ADMA Biologics Announces FDA Approval To Expand The Label For ASCENIVTM To Include Pediatric Immune Compromised Patients Two Years Of Age And Older

(MENAFN - GlobeNewsWire - Nasdaq) RAMSEY, N.J. and BOCA RATON, Fla., May 04, 2026 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (–ADMA– or the–Company–), a U.S. based, end-to-end ...